EMA Grants Orphan Status to EHP-102 for Treatment of Huntington’s
The European Medicines Agency (EMA) granted orphan designation to Emerald Health Pharmaceuticals’ (EHP) EHP-102 for the treatment of Huntington’s disease. Orphan status is given to medications designed to treat, prevent or diagnose rare life-threatening or chronically debilitating disorders that affect no more than five…